The Biden administration is poised to reveal the initial group of prescription drugs that will undergo price negotiations with Medicare, marking a significant development in the Democrats’ longstanding effort to lower drug costs by leveraging the government’s purchasing influence. The move is anticipated to be a focal point in President Biden’s re-election messaging, despite facing legal opposition from drug manufacturers. Medicare plans to release a list of the first 10 negotiable drugs, potentially including widely used medicines like Eliquis, Januvia, and Xarelto. This initiative, resulting from decades of political struggle, symbolizes a shift in the battle against the powerful pharmaceutical lobby. The negotiation process faces legal challenges, but it holds the potential to drive down average drug prices in the Medicare prescription drug program.